Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer

Yervoy (ipilimumab) - BMS

albumin-bound paclitaxel - Generic mfg.

oxaliplatin - Generic mfg.

iparomlimab (QL1604) - Qilu Pharma

Teysuno (gimeracil/oteracil/tegafur) - Nordic Group, Otsuka

Qibeian (iparomlimab/tuvonralimab) - Sound Biologics, Qilu Pharma

Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 10, 2026 - P2 | N=28 | Recruiting | Sponsor: Ruijin Hospital
New P2 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

http://clinicaltrials.gov/ct2/show/NCT07867392

Oct 10, 2026